LBODP041 Effects Of Sodium-glucose Co-transporter 2 Inhibitors (sglt-2 Inhibitors) On Adipokines And Inflammatory Biomarkers In Type2 Diabetic Patients

BACKGROUND: Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. SGLT-2 inhibitors reduce HbA1c and show favorable effects on body weight, blood pressure, lipid profile, arterial stiffness, and endothelial function. More importantly, SGLT-2 inhibitors have demonstrated impressive cardioprotective and renoprotective effects. The main mechanisms of cardioprotective effects have been attributed to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na+/H+ exchanger in myocardial cells, alteration in adipokines and cytokines production. This exploratory research aimed to observe the effects of Canagliflozin, Dapagliflozin, and Empagliflozin on select inflammatory biomarkers, adiponectin, for instance. METHODS: Comparison of serum adiponectin between baseline with 16-week after SGLT-2 inhibitors therapy were assessed in type 2 diabetic participants. Changes of chosen metabolic and anthropometric variables were discussed. RESULTS: At 16-week after SGLT-2 inhibitors treatment, a striking increment in mean serum adiponectin by 1.25 mcg/mL (95% CI: 0. 02, 2.48) or 81% was revealed. Furthermore, they showed a reduction of mean BMI 1.12% (95% CI: -1.74%, -0.50%), systolic blood pressure 1 mmHg (95% CI: -1.85, -0.72), diastolic blood pressure 1 mmHg (95% CI: -1.65, -0.52), fasting plasma glucose 34 mg/dL (95% CI: -51.66, -17.10), and HbA1c 0.73% (95% CI: -1.25%, -0.21%). No between-group differences were expressed with the other biomarkers. Serious side effects such as ketoacidosis, hypoglycemic status, genitourinary tract infection, acute kidney injury, or long-term dialysis dependence were not appeared. CONCLUSIONS: SGLT-2 inhibitors can improve changes in serum adiponectin which appreciatively benefit in cardiovascular outcomes among type 2 diabetes. Keywords: SGLT-2 inhibitors, adipokines, inflammatory biomarkers, type 2 diabetes mellitus, adiponectin, cardiovascular outcomes, cardioprotective, renoprotective Presentation: No date and time listed